- Products
- Reproduction
- Molecular diagnostics
- Careers
- About us
- Contacts
MSK-IMPACT® powered with SOPHiA DDM™ is an NGS panel designed for solid tumor profiling that includes 505 genes associated with common and rarer cancers. The panel was developed in collaboration with the prestigious Memorial Sloan Kettering Cancer Center (MSK).
By coupling with SOPHiA's unique DDM™ platform, the panel enables the detection of somatic variants such as SNV, InDel and CNV, in addition to TMB and MSI detection.
Paired DNA samples isolated from FFPE tumor tissue and blood are used for single patient testing. This can reduce the risk of false positivity.
Library preparation is based on hybridization capture technology. The kit is compatible with Illumina sequencers (NextSeq® and NovaSeq™).
The development of the MSK-IMPACT® panel is also closely linked to the development of the OncoKB® database used for targeted cancer therapy. The OncoKB® database contains a summary of genes and variants that can be targeted with concurrently approved drugs. It is these genes that the MSK-IMPACT® panel is largely focused on.
List of genes on request.
For more information, please contact us by e-mail: diagnostika@pentagen.cz